Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "mCRC" Clear all
Active, not recruiting Phase 1Phase 2 Interventional

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial

NCT04599140
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
CXCR1/2 Inhibitor SX-682, Nivolumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy

NCT02317627
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
KD025
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Glendale, Arizona • Santa Ana, California • Lake Charles, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Jul 23, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

NCT02083653
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC), Fluorouracil (5-FU), Capecitabine
Drug · Other
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 23, 2026, 9:33 PM EDT
Recruiting Phase 2 Interventional

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

NCT05705492
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Metastatic Colorectal Carcinoma (mCRC), Advanced Lung Carcinoma, Locally Advanced Hepatocellular Carcinoma
Interventions
Olanzapine, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy

NCT03007407
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
durvalumab, Tremelimumab
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
18
States / cities
Duarte, California • New Haven, Connecticut • North Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Jul 23, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus

NCT00597506
View directory record Official record
Conditions
Colorectal Adenocarcinoma
Interventions
Bevacizumab, Everolimus
Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Jul 23, 2026, 9:33 PM EDT
Recruiting Phase 3 Interventional

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
26
States / cities
Chandler, Arizona • Fullerton, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 9:33 PM EDT
Terminated Phase 1 Interventional

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

NCT02205398
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer
Interventions
INC280, cetuximab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Jul 23, 2026, 9:33 PM EDT
Completed Phase 1 Interventional

SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)

NCT01966289
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
CY, GVAX, SGI-110
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Jul 23, 2026, 9:33 PM EDT
Terminated Phase 2 Interventional Results available

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

NCT03549338
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, Carcinoma
Interventions
Sym004, Futuximab, Modotuximab
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2020 · Synced Jul 23, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

NCT01490866
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Axitinib, Bevacizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
12
States / cities
Jonesboro, Arkansas • Fort Myers, Florida • Pensacola, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Jul 23, 2026, 9:33 PM EDT
Completed No phase listed Observational

Detection of CTCs in Patients Undergoing Surgery for Stage IV Colorectal Cancer

NCT01722903
View directory record Official record
Conditions
Stage IV Colorectal Cancer, Liver Metastases, Lung Metastases
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Jul 23, 2026, 9:33 PM EDT
Terminated Phase 2 Interventional Results available

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

NCT04515394
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Tepotinib, Cetuximab
Drug · Biological
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • La Jolla, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Jul 23, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

NCT05104567
View directory record Official record
Conditions
Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Oesophageal Adenocarcinoma
Interventions
THOR-707, Pembrolizumab, Cetuximab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Duarte, California • Orlando, Florida • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Jul 23, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

NCT05952869
View directory record Official record
Conditions
Hypercholesterolemia, Familial Hypercholesterolemia
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Daphne, Alabama • Boca Raton, Florida • Cutler Bay, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 23, 2026, 9:33 PM EDT
Recruiting Phase 2 Interventional

Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History

NCT05446584
View directory record Official record
Conditions
Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder, Amnestic Mild Cognitive Impairment, Mild Traumatic Brain Injury, Concussion, Brain
Interventions
High Definition Transcranial Direct Current Stimulation
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 9:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

NCT06047379
View directory record Official record
Conditions
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab
Drug
Lead sponsor
Neonc Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Beverly Hills, California • Glendale, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 9:33 PM EDT
Completed No phase listed Observational

An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States

NCT06029010
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Multiple Locations, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Jul 23, 2026, 9:33 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)

NCT01652482
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-fluorouracil, Cetuximab, Irinotecan, Leucovorin, MEHD7945A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
19
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 9:33 PM EDT
Not listed Phase 2 Interventional

A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

NCT00931840
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
EZN-2208, Cetuximab and Irinotecan
Drug
Lead sponsor
Enzon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
35
States / cities
Tucson, Arizona • Alhambra, California • Bakersfield, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Jul 23, 2026, 9:33 PM EDT
Terminated Phase 1 Interventional

A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors

NCT02243917
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
CB-5083
Drug
Lead sponsor
Cleave Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Jul 23, 2026, 9:33 PM EDT
Withdrawn Phase 2 Interventional

A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer

NCT02615574
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
αDC1 vaccine, CKM
Biological · Drug
Lead sponsor
Pawel Kalinski
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Jul 23, 2026, 9:33 PM EDT
Terminated Phase 1 Interventional

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

NCT04060342
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma
Interventions
GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
Drug
Lead sponsor
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Jul 23, 2026, 9:33 PM EDT
Recruiting Phase 1 Interventional

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

NCT04485013
View directory record Official record
Conditions
Cancer
Interventions
TTX-080, pembrolizumab, cetuximab, FOLFIRI
Drug
Lead sponsor
Tizona Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
41
States / cities
Tucson, Arizona • Los Angeles, California • Newport Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jul 23, 2026, 9:33 PM EDT